Zyplast ® is a registered trademark of Inamed in Santa Barbara California, USPTO registration #2934996 issued on 3/22/05.
On the application for trademark, Zyplast ® is described as "collagen implant used for soft tissue augmentation".
Zyplast ® received FDA approval in 1985.
Zyderm ® and Zyplast ® about both injectable collagen implants. These collagen implants are used to smooth facial lines, wrinkles and scars. Zyderm ® and Zyplast ® are also used to provide lip border definition.
Zyderm ® and Zyplast ® work by supplementing the skin's natural collagen. More than one million people have, according the the official web site, been treated with either Zyderm ® or Zyplast ®.
The implants are "composed of highly purified bovine dermal collagen that is dispersed in phosphate buffered physiological saline containing 0.3% lidocaine." (inamed.com)
Zyderm ® and Zyplast ® implants are implemented to correct contour deformities of the dermis in certain cases. Please consult with your board certified plastic surgeon for more information.
Use of Zyderm ® and Zyplast ® implants requires a collagen test implant, which is administered 4 weeks prior to the surgical procedure. According to the information on the official web site (www.inamed.com), 97% of men and women tested can be treated with the Zyderm ® and Zyplast ® implants.
Four weeks prior to the procedure, Collagen Test Implant is administered intradermally into the volar forearm to determine if a patient has a sensitivity to the implants. Ninety-seven percent (97%) of men and women tested can be treated with Zyderm and Zyplast implants.
These implants underwent extensive clinical trials from 1976 to 1981, and the results were submitted to the FDA. As a result, the FDA approved Zyderm ® and Zyplast ® for consumer marketing in 1981 and 1985 respectively.
According to the information found there, "no other injectable collagen implants currently on the market have undergone such extensive study".
Hylaform ® is a registered trademark (reg. #2052997) of Genzyme Biosurgery Corporaton of Cambridge Massachusetts.
Genzyme and Inamed are associated for this product.
The original owner of the USPTO trademark registration is listed as Biomatrix,Inc of Ridgefield New Jersey. The USPTO registration date for Hylaform is listed as April 15, 1997, and, according to the trademark application on file at the USPTO web site, Genzyme became the trademark owner "by merger".
Hylaform ® is described as "pharmaceuticals; namely, a pre-packaged injectable biochemical; namely hylan gel for use in tissue augmentation".
FIRST USE: November 14, 1996.
Hylaform ® received FDA approval in April 2004, and, according to the information on Inamed's web site, "no pre-treatment skin test is needed". Immediate results are also indicated, and the hyaluronic acid found in the gel is a natural sugar found in all living cells. Hylaform ® works by binding water to skin to produce volume.
